Lisata Therapeutics (LSTA) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Passage Bio (PASG) over the past year, losing 52.6% versus a loss of 54.3%. Over five years, LSTA leads with a -93.4% price change compared with -98.1% for PASG. Lisata Therapeutics is the larger company by market cap ($13.0 million vs $12.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | PASG |
|---|---|---|
| Share price | $1.20 | $3.78 |
| Market cap | $12.96M | $12.16M |
| 1-day change | +2.56% | -1.95% |
| YTD return | -35.48% | -67.97% |
| 1-year return | -52.57% | -54.35% |
| 5-year return | -93.44% | -98.06% |
| EPS (TTM) | $-1.64 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $20.00 |
| 52-week low | $0.99 | $3.29 |
| Distance from 52-week high | -76.33% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | — | +310.05% |
| Average volume | 291.91K | 26.11K |
| Shares outstanding | 10.80M | 3.22M |
| Employees | 21 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
LSTA vs PASG FAQ
Which is bigger, Lisata Therapeutics or Passage Bio?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $12.96M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, LSTA or PASG?
LSTA returned -52.57% over the past 12 months, compared with -54.35% for PASG (price return, excluding dividends). Past performance does not predict future results.
Are Lisata Therapeutics and Passage Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Lisata Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Passage Bio.